Safety, Tolerability, and Pharmacokinetics of Multiple Dose Combinations of SION-451 and Complementary Modulators SION-2222 and SION-109 in Healthy Participants.

Abroad (travel likely)RecruitingPHASE1

Conditions

Cystic Fibrosis (CF)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

Nucleus Network, Brisbane, Queensland, Australia
Contact: Study coordinator (Gloria Wong, MBBS, PhD, FRACP) · g.wong@nucleusnetwork.com.au · +61 (07) 3707 2720
Nucleus Network, Melbourne, Victoria, Australia
Contact: Study coordinator (Nucleus Network Melbourne) · melbourne@nucleusnetwork.com.au · +61 (03) 8593 9801
Contact: Principal Investigator (Philip Ryan, MBBS, BMedSc, PhD, DPM, FFPM)

Study leads

Philip Ryan, MBBS, BMedSc, PhD, DPM, FFPM
Principal Investigator
Nucleus Network

View source on ClinicalTrials.gov

Similar trials

Other trials that are currently recruiting and may be relevant based on condition, treatment, phase, or location

A Phase 2 Study Evaluating Safety and Tolerability of RCT2100 (CFTR mRNA) in Healthy Participants and in Participants With CF

Cystic Fibrosis

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Tucson, United States

Study With Phage for CF Subjects With Pseudomonas Lung Infection

Chronic Pseudomonas Aeruginosa Infection · Cystic Fibrosis (CF)

Abroad (travel likely)RecruitingPHASE2

Birmingham, United States · Anchorage, United States

Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection

Cystic Fibrosis (CF) · Achromobacter Infection

Abroad (travel likely)RecruitingPHASE1

San Diego, United States · Pittsburgh, United States

Proof of Principle Study for an Efficacy Trial of Linaclotide for Cystic Fibrosis

Cystic Fibrosis (CF)

Abroad (travel likely)RecruitingEARLY_PHASE1

Nottingham, United Kingdom